title: Drug delivery performance of the mometasone furoate dry powder inhaler.
abstract: The mometasone furoate dry powder inhaler (MF-DPI) is a multiple-dose, breath-actuated inhaler that uses agglomerates of micronized MF and lactose. In vitro analyses evaluated dose uniformity, variability, and particle size distribution of the MF-DPI. Tests of first, middle, and end doses from 10 inhalers each of the 200-microg MF/inhalation and 400-microg MF/inhalation dose sizes found that delivered doses (doses emitted from the inhaler) ranged from 91% to 112% of claimed doses for all tested DPIs. The mean MF doses delivered at 28.3 L/min were 100% and 94% of the doses delivered at 60 L/min for the 200-microg and 400-microg dose sizes, respectively; the relative standard deviation of doses was < or = 6.1% within this range of inhalation rates. At a flow rate of 60 L/min, the mean delivered doses, compared to claimed doses for inspiration times of 1-3 sec, were 102-104% for the 200-microg dose size and 98.8-102% for the 400-microg dose size. The mean cumulative fraction of dose delivered at 60 L/min for 2 sec which consisted of particles of <6.5 microm in diameter was 39.9% (+/-2.5 SD; n = 9) for the 200-microg dose size and 35.6% (+/-3.4 SD; n = 9) for the 400-microg dose size. All MF-DPI inhalers tested were well within U.S. and European compendial standards and regulatory guidelines for dose uniformity. An appropriate and reproducible fraction of the delivered dose was within the optimal particle size range for therapeutic effectiveness.
authors.affiliation: Schering-Plough Research Institute, Kenilworth, New Jersey 07033-0530, USA. Tsong-Toh.Yang@spcorp.com
authors.forename: T T
authors.initials: TT
authors.lastname: Yang
authors.forename: S
authors.initials: S
authors.lastname: Li
authors.forename: B
authors.initials: B
authors.lastname: Wyka
authors.forename: D
authors.initials: D
authors.lastname: Kenyon
mesh_terms: D000280:Administration, Inhalation; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D005938:Glucocorticoids; D006801:Humans; D000068656:Mometasone Furoate; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D011208:Powders; D011244:Pregnadienediols / Q000008:administration & dosage*
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D011208:Powders; D011244:Pregnadienediols; D000068656:Mometasone Furoate